CoNaIn recommends moving forward with the modification of the CNV by lowering the age of application of the second dose of SRP to 15-18 months. It suggests promoting actions to increase vaccination coverage of the first and second doses, reinforce the Epidemiological Surveillance of the EFE and move forward with the recovery of schemes to close gaps in each age cohort.